eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2010
vol. 7
 
Share:
Share:
abstract:

TORAKOCHIRURGIA
Do NSCLC patients become sensitive to second-line erlotinib treatment after previous radiotherapy?

Paweł Krawczyk
,
Dariusz M. Kowalski
,
Kamila Wojas-Krawczyk
,
Maciej Krzakowski
,
Janusz Milanowski

Kardiochirurgia i Torakochirurgia Polska 2010; 7 (4): 411–414
Online publish date: 2011/01/03
View full text Get citation
 
Background : Erlotinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI) that has shown activity in recurrent NSCLC. One could speculate that sensitivity to erlotinib is dependent on the activated form of EGFR gene mutation in tumour cells. The radiation-induced activation of the EGFR pathway and EGFR gene mutation in cancer cells could arouse the response to EGFR-TKI agents.

Aim : The aim of the study was to evaluate the effectiveness of erlotinib in second- and third-line therapy according to the type of first-line therapy.

Material and methods : 102 patients with recurrent NSCLC, who had erlotinib administered in second- and third-line therapy, were divided into two groups: group A – included patients treated first-line with a combination of thoracic radiotherapy and cisplatin-based chemotherapy (n = 40); group B – patients treated with chemotherapy alone (n = 62). The efficacy of erlotinib was analysed based on chi-square, Cox logistic regression and Kaplan-Meier tests.

Results : Disease control and survival longer than 6 months during erlotinib administration were observed significantly more frequently in patients from Group A than from Group B (p < 0.05 and p < 0.005, respectively). Median time of overall survival was 16 months for Group A and only 5 months for Group B. Moreover, probability of survival was significantly higher in Group A than in Group B (p < 0.005, HR = 2.179, 95% CI: 1.339-3.546). Based on the Cox regression model, among 6 other prognostic factors, no application of radiotherapy in first-line treatment had a significant impact on the reduction of overall survival (p < 0.005, HR = 2.636, 95% CI: 1.385-5.015).

Conclusions : Our observations indicate that application of radiotherapy in first-line treatment has predictive rather than prognostic value for the efficacy of erlotinib second- or third-line therapy.
keywords:

radiotherapy, erlotinib, non-small cell lung cancer, predictive factor

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.